Navigation Links
Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
Date:4/14/2011

RESEARCH TRIANGLE PARK, N.C., April 14, 2011 /PRNewswire/ -- Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) will issue its first quarter earnings release after the market closes on April 27, 2011. Due to the pending merger with Grifols, S.A., Talecris will not be hosting a conference call to discuss its first quarter results.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com.


'/>"/>
SOURCE Talecris Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
2. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
4. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards
5. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
6. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
7. Talecris Added to NASDAQ Biotechnology Index
8. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
9. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
10. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
11. Talecris Biotherapeutics Announces Premerger HSR Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 6, 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... fourth quarter and fiscal year ended September 30, 2016. ... , , ... sciences and diagnostics company that develops and commercializes proprietary technologies and ... Achieved revenues of $1.4 million more than tripling prior ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... plasma technology platforms, announced today that the company has engaged in a collaborative ... Development Agreement (MRDA) with the CSU Office of the Vice President for Research. ...
(Date:12/6/2016)... MENLO PARK, Calif. , Dec. 6, 2016 ... of up to $150 million from the National ... Infectious Diseases and the Division of AIDS (NIAID-DAIDS) ... microbicides and other non-vaccine pre-exposure (PreP) agents. Under ... suite of preclinical product development services for candidate ...
(Date:12/5/2016)... ... December 05, 2016 , ... This composition patent, U.S. Patent ... The composition claims are not limited to any particular process to make ... polymers, carbon fibers, graphene, and other materials. A continuation application, U.S. Patent ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
Breaking Biology News(10 mins):